c-Ki-ras oncogene amplification and FGF2 signaling pathways in the mouse Y1 adrenocortical cell line

The mouse Y1 adrenocortical tumor cell line is highly responsive to FGF2-(Fibroblast Growth Factor 2) and possesses amplified and over-expressed c-Ki-ras proto-oncogene. We previously reported that this genetic lesion leads to high constitutive levels of activation of the c-Ki-Ras-GTP→PI3K→Akt signaling pathway (Forti et al. 2002). On the other hand, activation levels of another important pathway downstream of c-Ki-Ras-GTP, namely, Raf→MEK→ ERK, remain strictly dependent on FGF2 stimulation (Rocha et al. 2003). Here we show that, first, FGF2 transiently up-regulates the c-Ki-Ras-GTP→PI3K→Akt pathway, in spite of its high basal levels. Second, c-Ki-Ras-GTP transient up-regulation likely underlies activation of the ERK1/2 pathway by FGF2. Third, c-Ki-Ras-GTP high basal levels suppress activation of the c-H-Ras onco-protein. But, Y1 cells, expressing dominant negative mutant RasN17, display a rapid and transient up-regulation of c-H-Ras-GTP upon FGF2 treatment. Elucidation of FGF2-signaling pathways in Y1 tumor cells can uncover new targets for drug development of interest in cancer therapy.

amplifi cation (Meneghini et al. 1971, Glover et al. 1982).Thus, in a pioneering series of publications, the laboratories of Pavan and Lara concurred to discover, experimentally demonstrate and conceptualize gene amplifi cation as a basic biological phenomenon.
During the eighties, amplifi cation of oncogenes became progressively recognized as an important part of the genetic bases underlying both carcinogenesis and resistance of tumor cells to drug therapy (Schwab 1999).c-Ki-Ras was the fi rst oncogene reported amplifi ed, over-expressed and located in abnormal chromosomes of the mouse Y1 adrenocortical tumor cell line (Schwab et al. 1983).Y1, isolated by Yasumura et al. (1966), is a phenotyp-ically stable, ACTH-responsive, steroid-secreting, clonal cell line that expresses high levels of ACTH-Receptors, closely mimicking fasciculate cells from the normal adrenal cortex.Y1, along of the last forty years, have remained an adrenocortical cell line singularly appropriate for studies of steroidogenesis and ACTH regulatory pathways (Schimmer 1979, Rainey et al. 2004).More recently, we have been investigating control of cell cycle in Y1 adrenocortical cells, aiming to unravel molecular mechanisms underlying G0→G1→S transition of adrenal cell cycle (Armelin et al. 1996, Rocha et al. 2003).Although the malignant phenotype of Y1 cells includes rapid tumor growth in Nude mice, evasion from apoptosis and limitless replicative potential, this cell line retains a remarkably tight control of the G0→G1→S transition, being highly permissive to mitogenic stimulation by FGF2.In addition, from a cancer biology viewpoint, it is timely to analyze FGF2 signaling pathways in a tumor cell line displaying over-expression of the c-Ki-ras oncogene.
The ras oncogenes (H-, Ki-and N-ras) encode regulated GTPases switches of 21kDa that mediate, upstream signals initiated in membrane TKR (Tyr-kinase receptors), and, downstream signaling pathways that modulate gene transcription (Malumbres and Barbacid 2003).The ras gene family has been extensively studied over the last twenty years, mainly due to its growing importance in normal cell cycle control and cancer biology.The ras signaling pathways are now understood in great detail at the molecular levels, but this signaling network is not simple, with multiple points of bifurcation and feedbacks.Besides, Ras proteins have been described as the point of convergence of different pathways involved in diverse biological responses like: proliferation, survival, differentiation and tumorigenesis.Mutations and/or amplifications of c-Ki-ras are among the genetic lesions found in 90% of pancreatic, 50% of colon and 35% of lung human tumors (Bos 1990, Bardeesy andDePinho 2002).Presently, components of signaling pathways upstream and downstream of Ras oncoproteins are important targets in drug development for cancer therapy (Downward 2003).However, this strategy has recognized limitations.Ras-signaling pathways are physiologically important for all normal cells and drugs that block Ras signaling are likely to have strong deleterious side effects in cancer patients.
In Y1 adrenocortical cells c-Ki-ras oncogene amplifi cation (Schwab et al. 1983, Kimura andArmelin 1988) causes over-expression of both c-Kiras mRNA and protein, leading to high basal levels of c-Ki-Ras-GTP (Forti et al. 2002) and, consequently, partial deregulation of cell cycle control.Downstream of chronic c-Ki-Ras-GTP high levels the PI3K/Akt pathway is kept constitutively active, suppressing the expression of the CDK-inhibitor p27 kip1 protein (Forti andArmelin 2000, Forti et al. 2002) and partially deregulating transcription of the c-myc gene (Lepique et al. 2004).Attenuation of the constitutive levels of c-Ki-Ras-GTP in G 0 /G 1 -arrested Y1 cells, by enforced expression of the dominant negative mutant HaRasN17, renders the PI3K/Akt pathway stringently dependent on mitogen activation (Forti et al. 2002).In spite of the chronic high levels of c-Ki-Ras-GTP, Y1 cells retain stringent dependency of the ERK1/2 pathway on mitogens, accounting for the remarkable cell cycle control displayed by these cells upon serum step down and serum step up (Armelin et al. 1977, 1996, Lotfiand Armelin 2001, Rocha et al. 2003).
In G 0 /G 1 cell cycle-arrested Y1 cells, FGF2 elicits a strong mitogenic response, involving: rapid ERK-MAPK activation (2-5min) and late S phase entry (8-9h), detected by BrdU labeling (Armelin et al. 1996, Lotfiet al. 1997, Lotfiand Armelin 2001, Schwindt et al. 2003, Rocha et al. 2003).But, FGF2, in addition to its classical mitogenic activity, concomitantly triggers a non-apoptotic cell death and/or senescence, by a process dependent on the high chronic levels of c-Ki-Ras-GTP found in Y1 cells (Costa et al. 2004, E.T. Costa and H.A Armelin, unpublished results).To elucidate the molecular mechanisms underlying this novel FGF2 death-effect, we are carefully analyzing FGF2 signaling in Y1 cells, particularly in respect to connec-An Acad Bras Cienc (2006)  78 (2) tions between FGF2-receptors (FGF2Rs) and Rasinitiated pathways.In this paper we report on the earliest activation steps of FGF2 signaling, namely, activation of Ras onco-proteins and of both ERK and PI3K/Akt pathways.

MATERIALS AND METHODS
Cell Line cultivation: Cells from the mouse Y1 adrenocortical tumor cell line (Yasumura et al. 1966) and Y1-RasN17transfectant clonal lines carrying dominant negative mutant genes ras N17, were grown in 10% FCS-DME minus or plus 100 µg/mL G418.To arrest the cell cycle at G0/G1 boundary, we incubated cells growing exponentially in 10% FCS-DME for 48 h in SFM (serum-free medium).In SFM, Y1 cells are viable and fully responsive to FGF2, AVP and/or ACTH.

Y1-RasN1-1.5 and Y1-RasN17-3.1 Clonal Lines:
Plasmid pMMrasDN is a construct containing the rasN17 under the control of the MMTV promoter (Forti et al. 2002) obtained from Dr. L. Feig (Tufts University, Boston) that was transfected into Y1 cells and neutrally selected with G418 to generate clonal lines exhibiting dexamethasone-inducible RasN17 protein.Y1-RasN17-3.1 transfectant clone express RasN17 in a dexamethasone dose dependent manner: 10 −10 M dexamethasone is suffi cient to increase RasN17 protein levels by more than 10 fold.

Ras-GTP assay by specific binding to RBD-GST (Raf1 Binding Domain-Glutathione S Transferase) fusion protein, covalently linked to
Sepharose beads: Cells were lysed in 50mM Tris-HCl pH 8.0, 0.5% Nonidet P-40, 150 mM NaCl, 1% SDS, 0.5% sodium deoxycholate, 10 µg/mL leupeptin, 10 µg/mL aprotinin.Lysates were collected by centrifugation (10 4 g for 10 min at 4 • C) and kept frozen.Aliquots of cell lysates containing 500 µg protein, quantifi ed by the Bradford assay, were incubated with RBD-GST beads for 60 min at 4 • C to bind Ras-GTP.Beads, carrying bound Ras-GTP and recovered by centrifugation, were washed with lysis buffer at 4 • C, suspended in SDS-PAGE sample buffer (100 mM Tris-HCl pH 7.5, 200 mM DTT, 4% SDS, 20% glycerol, 0.2% bromophenol blue), and loaded on 12% SDS-PAGE gels.After electroblotting onto Hybond-C nitrocellulose membranes, using a semidry Bio-Rad apparatus, activated c-Ki-Ras and c-H-Ras were detected with polyclonal antibodies specifi c for, respectively, c-Ki-Ras and c-H-Ras (Santa Cruz).Each sample of activated Ras, recovered by these procedures, was compared in Western blots to total Ras in 50 µg cell-protein aliquots of the respective lysate not incubated with RBD-GST beads.
To analyze the phenotypic effects of the constitutive c-Ki-Ras-GTP levels, we developed transfectants of Y1 cells carrying the human dominant negative mutant Ha-rasN17 (Feig and Cooper 1988) under the control of the MMTV conditional promoter.In these Y1-RasN17-transfectants (R3.1 and R1.5 clones), dexamethasone induces the H-rasN17 transgene causing drastic reduction of c-Ki-Ras-GTP levels, but without completely blocking cell cycle, allowing analysis of both G1 progression and cell proliferation (Forti et al. 2002, Lepique et al. 2004).
In G 0 /G 1 -arrested cells of the Y1-RasN17, clone3.1,transfectant line, c-Ki-Ras-GTP levels are maintained constitutively high, but, upon dexamethasone treatment, c-Ki-Ras-GTP decreases to negligible levels [Fig.2].However, dexamethasone induction of the H-RasN17 dominant negative transgene is not suffi cient to interrupt activation of the Ras→Raf→MEK→ERK pathway by signals initiated in FGF2Rs, as shown by the pattern of ERK1/2 phosphorylation displayed in Fig. 2.
In parental Y1 cells and Y1-RasN17 transfectants in the absence of dexamethasone, mouse endogenous c-H-Ras-GTP is maintained at negligible levels, irrespective of FGF2 stimulation (not shown).However, in G 0 /G 1 -arrested Y1-RasN17-3.1 transfectants treated with dexamethasone, FGF2 causes a very rapid transient increase in c-H-Ras-GTP levels (Fig. 3).Therefore, high basal levels of c-Ki-Ras-GTP suppress c-H-Ras activation, whereas under minimal basal levels of c-Ki-Ras-GTP Y1 cells respond to signals initiated in FGF2Rs with rapid and concomitant activation of both c-Ki-Ras and c-H-Ras proteins, resembling normal cells.
We previously reported that Y1 cells exhibit high basal levels of activated Akt dependent on chronically elevated c-Ki-Ras-GTP levels and PI3K activity (Forti et al. 2002).In Y1-RasN17 transfectant lines dexamethasone causes severe reduction of both c-Ki-Ras-GTP levels and phosphorylated-Akt, which are transiently restored by FGF2 treatments.But, PI3K inhibitors block phosphorylation of Akt promoted by FGF2 (Forti et al. 2002), indicating that the whole pathway is comprised by FGF2R→c-Ki-Ras-GTP→PI3K→Akt.Thus, the genetic lesion of Y1 cells, namely, amplifi cation of the c-Ki-ras gene, leads to high basal levels of c-Ki-Ras-GTP, keeping the PI3K→Akt pathway constitutively activated.Here we confi rm and extend these observations showing that, under low or high basal levels of c-Ki-Ras-GTP, signals initiated in FGF2Rs trigger a sequential wave of transient activations, fi rst, with c-Ki-Ras-GTP by 0.5 min [Fig.1A], second, with ERK-phosphorylation by 5 min [Figs.1C  and 2] and third, Akt-phosphorylation by 5 min (Figs.4A and 4B).However we cannot completely rule out the possibility that signals initiated in FGFR, via adaptor proteins FRS2→Grb2→Gab1, might directly activate PI3K, bypassing SOS→Ras-GTP (Ong et al. 2001).
We also had previously shown that, in Y1 cells, FGF2 mitogenic activity is antagonized by ACTH (Armelin et al. 1996, Lepique et al. 2004) and AVP (arginine-vasopressin) (Schwindt et al. 2003).These inhibitory effects of ACTH and AVP follow different molecular mechanisms (Lepique et al. 2004, Schwindt et al. 2003), however both converge to PI3K→Akt pathway, as presented in Fig. 5. ACTH, via cAMP/PKA, promotes dephosphorylation of basal activated-Akt, but cannot block transient activation of Akt elicited by FGF2 [Fig.5].Therefore ACTH does not block signals initiated in FGF2-Receptors, however it inactivates one specifi c downstream effector of c-Ki-Ras-GTP chronic high levels, namely, basal activated-Akt.On the other hand, AVP antagonizes FGF2-Receptor signals, preventing the transient activation of Akt by FGF2, but without any effect on basal levels of phosphorylated Akt [Fig.5].
In Y1 adrenocortical tumor cells, the results reported here imply that: a) activated constitutive levels of c-Ki-Ras-GTP→PI3K→Akt do not preclude transient up-regulation of this pathway by An Acad Bras Cienc (2006)  78 (2)  (Schlessinger 2004).This scheme overlooks the recognized fact that Ki-Ras and H-Ras proteins do not co-localize in membranes of normal cells (Hancock 2003).In the scheme PTEN mediates the inhibitory effects of AVPR over PI3K activity, this is a tentative conclusion based on recent observations (F.L. Forti and H.A. Armelin, unpublished results).
FGF2, b) c-Ki-Ras-GTP transient up-regulation likely underlies activation of ERK1/2 by FGF2, c) c-Ki-Ras-GTP high chronic levels suppress c-H-Ras activation by FGF2.These results and respective interpretations are summarized in the scheme of Fig. 6 depicting the early steps of activation of Ras-signaling pathways in Y1 adrenocortical cells.
In G0/G1-cell cycle-arrested Y1 cells, FGF2 triggers a canonical mitogenic response, involving G1 progression and S phase entry (Lotfiand Armelin 2001, Rocha et al. 2003), and, a nonapoptotic cell death and/or senescence (Costa et al. 2004, E.T. Costa and H.A. Armelin, unpublished results).We have seen that reduction of c-Ki-Ras-GTP basal lev-els by enforced expression of the dominant negative mutant RasN17 recovers activation of both c-Ki-Ras and c-H-Ras by FGF2 (this paper) and, also, renders Y1 cells resistant to this novel FGF2 cell death-effect (Costa et al. 2004, E.T. Costa and H.A. Armelin, unpublished results).These observations suggest that a FGF2-triggered cell death-process, independent of the well-known FGF2-mitogenic activity, might exist as a natural unsuspected mechanism specifi c for restraining oncogene-induced proliferation of tumor cells.Hence, full elucidation of the signaling pathways activated by FGF2 in Y1 adrenocortical cells promises to uncover novel targets for drug development of interest in cancer therapy.